Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 2
2015 pubmed 23 citations

Pathogenic nontuberculous mycobacteria resist and inactivate cathelicidin: implication of a novel role for polar mycobacterial lipids.

Honda. Jennifer R JR; Hess. Tamara T; Malcolm. Kenneth C KC; Ovrutsky. Alida R AR; Bai. Xiyuan X; Irani. Vida R VR; Dobos. Karen M KM; Chan. Edward D ED; Flores. Sonia C SC

Key Findings

  • NTM species are broadly resistant to the antimicrobial peptide LL‑37.
  • The resistance isn’t caused by the bacteria’s glycopeptidolipid (GPL) components.
  • LL‑37’s activity is reduced after exposure to NTM, likely because NTM lipids inactivate the peptide, and some NTM grow more when LL‑37 is present.

Practical Outcomes

  • For DIY health enthusiasts, taking or using LL‑37 to fight NTM lung infections is unlikely to work and could be counter‑productive. Focus on other antimicrobial strategies or therapies for these infections rather than relying on LL‑37.

Summary

The study shows that certain lung‑infecting bacteria called nontuberculous mycobacteria (NTM) can shrug off the human antimicrobial peptide LL‑37 and even neutralize it with their own lipids, meaning LL‑37 isn’t effective against these bugs and might even help them grow in some cases.

Abstract

Nontuberculous mycobacteria (NTM) are a large group of environmental organisms with worldwide distribution, but only a relatively few are known to be pathogenic. Chronic, debilitating lung disease is the most common manifestation of NTM infection, which is often refractory to treatment. The incidence and prevalence of NTM lung disease are increasing in the United States and in many parts of the world. Hence, a more complete understanding of NTM pathogenesis will provide the foundation to develop innovative approaches to treat this recalcitrant disease. Herein, we demonstrate that several species of NTM show broad resistance to the antimicrobial peptide, cathelicidin (LL-37). Resistance to LL-37 was not significantly different between M. avium that contain serovar-specific glycopeptidolipid (GPL, M. aviumssGPL) and M. avium that do not (M. aviumΔssGPL). Similarly, M. abscessus containing non-specific GPL (M. abscessusnsGPL(+)) or lacking nsGPL (M. abscessusnsGPL(-)) remained equally resistant to LL-37. These findings would support the notion that GPL are not the components responsible for NTM resistance to LL-37. Unexpectedly, the growth of M. abscessusnsGPL(-) increased with LL-37 or scrambled LL-37 peptide in a dose-dependent fashion. We also discovered that LL-37 exposed to NTM had reduced antimicrobial activity, and initial work indicates that this is likely due to inactivation of LL-37 by lipid component(s) of the NTM cell envelope. We conclude that pathogenic NTM resist and inactivate LL-37. The mechanism by which NTM circumvent the antimicrobial activity of LL-37 remains to be determined.

Study Information

Provider

pubmed

Year

2015

Date

2015-05-18T00:00:00.000Z

DOI

10.1371/journal.pone.0126994

Citations

23

References

55